XML 18 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 09, 2023
Jun. 30, 2022
Document Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-39527    
Entity Interactive Data Current Yes    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Security Exchange Name NASDAQ    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Trading Symbol PRLD    
Entity Registrant Name PRELUDE THERAPEUTICS INC    
Entity Central Index Key 0001678660    
Entity Current Reporting Status Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Shell Company false    
Entity Ex Transition Period false    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 81-1384762    
Entity Address, Address Line One 200 Powder Mill Road    
Entity Address, City or Town Wilmington    
Entity Address, State or Province DE    
Entity Address, Postal Zip Code 19803    
City Area Code 302    
Local Phone Number 467-1280    
Entity Common Stock, Shares Outstanding   47,912,869  
ICFR Auditor Attestation Flag false    
Entity Public Float     $ 65.3
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Philadelphia, Pennsylvania    
Documents Incorporated by Reference

Portions of the Registrant’s Definitive Proxy Statement (“Proxy Statement”) relating to the 2023 Annual Meeting of Stockholders will be filed with the Commission within 120 days after the end of the Registrant’s 2022 fiscal year pursuant to Regulation 14A and is incorporated by reference into Part III of this Report. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.